CClinicalTrials.gg
RecruitingNCT05449522Updated Aug 16, 2024

Vitamin D for Critically Traumatic Patients

An interventional study of Vitamin D and Placebo in Vitamin D Deficiency and Major Trauma, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 4 years 2 months after the study started (first participant enrolled May 2018, registered Jul 2022).
  • Started May 2018; still recruiting 8 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Trauma has been an important global public health issue. Yet it is the sixth cause of death in Taiwan, trauma brings great negative impact to national productivity since it presents specifically as the leading cause of death for the population aged below 40 years. According to the national databank from Formosa Association for the Surgery of Trauma, mortality rate in critically traumatic patients with injury severity score (ISS) ≥ 25 is as high as 23%. Vitamin D, a pleiotropic hormone, regulates directly functions of most organs and immune system. It has been proven that vitamin D insufficiency or deficiency would deteriorate survival of critically ill patients, while supplementation of high-dose vitamin D ameliorates the clinical outcomes. This study investigates whether multiple high doses of vitamin D supplementation in one week can decrease the mortality and morbidity in critically traumatic patients. The serum levels of calcidiol and PTH will be measured on Day 0, Day 3, Day 10, Day 15, Day 30 and Day 60 before and after vitamin D supplementation.

02

Conditions studied

  • Vitamin D Deficiency
  • Major Trauma

Browse trials for

Keywords

  • Vitamin D
  • Major Trauma
03

In context

Vitamin D Deficiency

773 studies on the registry are indexed under Vitamin D Deficiency; 62 are open to participants now.

This study's planned enrollment of 100 is above the median of 77 across 564 interventional studies indexed under Vitamin D Deficiency.

Browse Vitamin D Deficiency studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 568 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Major trauma adult (> 20 years old) with Injury Severity Score equal or higher than 9, who is admitted to ICU

Exclusion criteria

Exclusion Criteria:

Patients with the following conditions:

  • Chronic liver disease
  • Contraindication to enteral feeds
  • Hypercalcemia
  • Current use of vitamin D, estrogen, or medications for bone disease
  • High risk of hypercalcemia, ex. metastatic cancer, primary hyperparathyroidism, sarcoidosis, multiple myeloma
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Experimental group will receive 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) theoretically to achieve sufficient level of vitamin D.

    Dietary Supplement: Vitamin D

  • Placebo comparator
    Control group

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementVitamin D

    High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube

  • Dietary supplementPlacebo

    Medium-chain triglyceride (MCT)

06

What researchers measure

Primary outcomes

  1. Mortality

    Mortality in ICU

    Time frame: up to 3 months after discharge

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital
    Taipei, Taiwan
    • Yin-Yi Han, MD, PhD · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05449522
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Jul 8, 2022
Start date
May 1, 2018
Primary completion
Jan 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Aug 16, 2024

Study contacts

Yin-Yi Han, MD, PhD
Contact
yyhan@ntuh.gov.tw
886-972651405
Yin-Yi Han, MD, PhD
principal investigator · National Taiwan University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion